‘Pioneering’ new weight-loss jab RES-010 could help keep weight off even after users stop taking it
A new Jab type that deals with the underlying causes of obesity can help people maintain weight loss even if they stop taking.
The so-called res-010 drug is designed to block a RNA molecule called Mir-22 called “main controller ğinde when it comes to the body uses fat.
Researchers hope that a weekly jab can control the body’s fat and mitochondria production, small structures that provide energy to cells, and small structures that provide changes when body fat is organized and function.
Dr. Riccardo Panella, the founding partner and general manager of Turin -based Biotech Resalis Therapeutics, said: “Instead of reducing the appetite, the body’s use of fat increases the production and activity of mitochondria and strengthens the ‘batteries’, and helps to convert white oils to energy, brown oil.
“It is less likely to gain weight because it affects these basic ways.”
Studying long -term weight loss was the collapse of drugs such as Mounjaro, Özempic and Wegovy, which was taken by approximately 1.5 million people in the UK.
These drugs are GLP-1 agonists, which are mainly used to control blood sugar levels, but reduce food requests and cause rapid weight loss.
However, the British Institute of Health and Care Excellence (NICE), which is the health observer of the UK, emphasized that many people have gained weight if they are not sufficiently supported after stopping treatment.
A study published in the journal BMC Medical Eight, 12 and 20 weeks after the participants stopped the drugs, he found significant weight gain periods.
Mounjaro manufacturer Eli Lilly, said the drug price of the drug in August 170 percent, he said. The movement has already caused panic among many people who buy the drug, and long -term users are expected to increase extra 100 £ each month at higher doses.
In the research presented at the annual meeting of the European Diabetes Study Association in Vienna, Austria, scientists found that they lost weight despite the same amount of eating with the mice that were not treated.
According to an abstraction presented at the meeting, mice did not gain weight after the drug was stopped.
Another study examining the safety of jab in humans is now in its early stages.
“Res-010, for example, is leading a new RNA class class that represents the body’s metabolism in order to produce long-term weight loss and advanced metabolic health by improving liver health, for example.
Surrey University Nutrition Associate Professor Dr. Adam Collins added: “I think mechanically, this is the storage of fat tissue (fat cells) storage and mitochondrial function (eg fat burning and thermogenesis) without knowing their direct effects.
“Before interpreting the results of any general weight loss, it is important to see the full paper and understand the mechanical logic behind the Res-10 and the proven metabolic effects.”
